Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–10 of 10 results
Advanced filters: Author: Sandra Misale Clear advanced filters

  • Cancer patients often respond well to primary treatment but then develop resistance. Here, Misale et al. show that dual treatment with EGFR and MEK inhibitors block resistance in mice containing patient-derived xenografts and provide a mathematical model that describes the temporal development of resistant tumour clones.

    • Sandra Misale
    • Ivana Bozic
    • Alberto Bardelli
    ResearchOpen Access
    Nature Communications
    Volume: 6, P: 1-9

  • Twelve early-career investigators share their thoughts on the experiences they had starting their laboratories in 2023 and reflect on the opportunities they seized and the challenges they faced.

    • Joanna Achinger-Kawecka
    • Santiago Correa
    • Caroline J. Watson
    Reviews
    Nature Cancer
    Volume: 4, P: 1630-1635

  • The initial discovery of an inhibitor of KRAS G12C revolutionized the KRAS field. Since then, more-potent G12C-specific inhibitors, newer allele-specific inhibitors and combinations based on KRAS targeting have advanced through clinical trials, which has led to approval by the US Food and Drug Administration of the first KRAS–EGFR inhibition combinations.

    • Sandra Misale
    Comments & Opinion
    Nature Cancer
    Volume: 6, P: 1913-1915

  • In a zebrafish model of human cutaneous and acral melanomas, CRKL amplification causes tumours to favour a fin location, indicating that tumour location is determined by both the driver oncogenes and the pre-existing positional identity gene program.

    • Joshua M. Weiss
    • Miranda V. Hunter
    • Richard M. White
    Research
    Nature
    Volume: 604, P: 354-361

  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have revolutionized the treatment of EGFR-mutant non-small cell lung cancer; however, secondary resistance limits their efficacy, emphasizing the need for newer approaches. A study now shows preclinical development of allosteric EGFR inhibitors that overcome acquired therapy resistance.

    • Michelangelo Marasco
    • Sandra Misale
    News & Views
    Nature Cancer
    Volume: 3, P: 381-383

  • A subset of patients treated with selective TRK inhibitors (including the newly approved larotrectinib) develop off-target resistance mediated by genomic acquisition of MAPK pathway-activating alterations, and may benefit from combined targeted therapy.

    • Emiliano Cocco
    • Alison M. Schram
    • Maurizio Scaltriti
    Research
    Nature Medicine
    Volume: 25, P: 1422-1427